Nativis bolsters boardroom with new director

pharmafile | February 22, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nativis 

Nativis Inc., a clinical stage life science bio-electronic company, has announced the appointment of Dr Una Ryan to its board of directors. Ryan joins the board as a board member of 11 years at AMRI, a global contract research and manufacturing company. For 24 years, she has been a Research Professor of Medicine at Boston University.

Ryan commented upon her appointment, “I am excited to join the Nativis team, and look forward to helping guide the company through the development of its unique technology platform. Nativis’ ulRFE technology represents an unprecedented opportunity to advance a new wave of treatment for recurrent glioblastoma multiforme and other health care indications, and I believe that with the right resources and strategies, the company can position itself for future success.”

“We are thrilled to be able to continue to diversify our board of directors and welcome Una, a distinguished entrepreneur, biologist and healthcare executive,” stated Nativis CEO Chris Rivera upon the appointment of Ryan. “Una brings a broad range of experience in the life science and investment arenas to the board, and her insight will be of great value to Nativis as we continue to develop and seek long term partners for of our novel ulRFE technology. Una’s background in global health and developing medical technologies adds significantly to the diversity of our other Directors’ extensive industry experience, which includes, for example; cyber-security, disruptive technologies, financial management, venture capital and bio-pharmaceutical development.”

Related Content

No items found

Latest content